First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.

被引：19
|
作者：
Roohullah, Aflah
Ganju, Vinod
Zhang, Faming
Zhang, Lei
Yu, Ting
Wilkinson, Kate
Cooper, Adam
de Souza, Paul
机构：
[1] South Western Sydney LHD, Liverpool, Australia
[2] Peninsula & Southeast Oncol, Frankston, Vic, Australia
[3] HanX Biopharmaceut Inc, Hangzhou, VA, Peoples R China
[4] Sydney Southwest Private Hosp, Liverpool, NSW, Australia
[5] St George Private Hosp, Liverpool, NSW, Australia
[6] St George Private Hosp, Kogarah, NSW, Australia
[7] Univ Western Sydney, Sch Med, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.2517
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2517
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study
    Desai, Jayesh
    Markman, Benjamin
    Friedlander, Michael
    Gan, Hui
    Horvath, Lisa
    Townsend, Amanda
    Millward, Michael
    Jameson, Michael
    Yen, Chia-Jui
    Hou, Ming-Mo
    Hou, Jeannie
    Wu, John
    Liang, Liang
    Deva, Sanjeev
    CANCER RESEARCH, 2019, 79 (13)
  • [42] A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY OF THE ANTI-CD200R1 ANTIBODY 23ME-00610 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
    Rasco, Drew
    Razak, Albiruni
    Schmidt, Maike
    Kell, Sariah
    Glatt, Dylan
    Belshaw, Erin
    Majeed, Sophia
    Kummar, Shivaani
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A790 - A790
  • [43] Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers
    Hou, Ming-Mo
    Ho, Ching-Liang
    Lin, Hsuan-Yu
    Zhu, Yunting
    Zhang, Xiaodi
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1315 - 1323
  • [44] A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS: INITIAL DOSE-ESCALATION RESULTS
    Johnson, Melissa
    Lakhani, Nehal
    Girda, Eugenia
    Olszanski, Anthony
    Fong, Lawrence
    Han, Hyunsil
    Casey, Kerry
    Li, Siyu
    Visich, Jennifer
    Skokos, Dmitris
    Seebach, Frank
    Lowy, Israel
    Fury, Matthew
    Mathias, Melissa
    Segal, Neil
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A767 - A768
  • [45] Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers
    Ming-Mo Hou
    Ching-Liang Ho
    Hsuan-Yu Lin
    Yunting Zhu
    Xiaodi Zhang
    Investigational New Drugs, 2021, 39 : 1315 - 1323
  • [46] A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma.
    Iyer, Gopa
    Gao, Xin
    Rasco, Drew W.
    Milowsky, Matthew I.
    Garmezy, Benjamin
    Rivera, Ildefonso I. Rodriguez
    Tepper, Jennifer
    Moles, Melissa Ann
    Gjini, Evisa
    Bowden, Michaela
    Meyers, Michael L.
    Bellmunt, Joaquim
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS709 - TPS709
  • [47] A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
    Nemunaitis, John J.
    Small, Karen A.
    Kirschmeier, Paul
    Zhang, Da
    Zhu, Yali
    Jou, Ying-Ming
    Statkevich, Paul
    Yao, Siu-Long
    Bannerji, Rajat
    JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11
  • [48] A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
    John J Nemunaitis
    Karen A Small
    Paul Kirschmeier
    Da Zhang
    Yali Zhu
    Ying-Ming Jou
    Paul Statkevich
    Siu-Long Yao
    Rajat Bannerji
    Journal of Translational Medicine, 11
  • [49] Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies
    Ferrario, Cristiano
    Laurin, Julie
    Van Kempen, Leon
    Lambert, Caroline
    Spatz, Alan
    Markova, Oksana
    Batist, Gerald
    Langleben, Adrian
    Filion, Mario
    Jolivet, Jacques
    CANCER RESEARCH, 2017, 77
  • [50] Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
    O'Cearbhaill, R. E.
    Moore, K. N.
    Yeku, O.
    Liu, J. F.
    Bouberhan, S.
    Hamilton, E. P.
    Hou, J. Y.
    Van Nieuwenhuysen, E.
    Papadimitriou, K.
    Yoo, S-Y.
    Govindraj, S.
    Brouwer-Visser, J.
    Peterman, M.
    Schmidt, T.
    Barnes, B.
    Madia, P.
    Zhu, M.
    Uldrick, T. S.
    Miller, E. A.
    O'Malley, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S516 - S517
12345